“We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a compelling body of evidence ...
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate in H2 2024 A Phase 2 trial ...
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
“We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a ...
Some results have been hidden because they may be inaccessible to you